JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vulva has been treated in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust in Cambridge, England.
Read more here.
![[Cyabra on Calcalist] Watch how Cyabra uses its capabilities to uncover Pro-Hamas fake news and propaganda](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
